Shinohara Masakazu, Serhan Charles N
The Integrated Center for Mass Spectrometry, Kobe University Graduate School of Medicine.
J Atheroscler Thromb. 2016 Jun 1;23(6):655-64. doi: 10.5551/jat.33928. Epub 2016 Apr 6.
Acute inflammation is a fundamental, protective response that orchestrates immune system to address harmful stimuli both from within and via invasion. New evidences indicate that the resolution of acute inflammation is not simply passive but active and highly regulated processes coordinated by new families of potent bioactive lipid mediators (LMs), coined specialized proresolving mediators (SPMs). These SPMs are biosynthesized from n-3 polyunsaturated fatty acids. Low concentrations of SPM (nM range) stimulate proresolving cellular processes, such as inhibition of neutrophil infiltration, enhancement of macrophage phagocytosis of bacteria and efferocytosis of cellular debris, and reduction of inflammatory pain through specific G-protein coupled receptors.Of the many bioactive mediators that regulate inflammation resolution, low-dose carbon monoxide (CO) functions as a tissue-protective gaso-transmitter that is endogenously produced by the heme oxygenase (HO) system. Specific SPMs activate the HO system, which in turn enhances endogenous CO production locally, thus establishing a protective feed-forward circuit between SPMs and CO. In addition, treatment with low-dose CO and SPMs exerts protective effects against ischemia/reperfusion injury by decreasing leukocyte-platelet interaction and proinflammatory LM levels.Recent studies reviewed herein assessed the impact of SPMs and low-dose inhaled CO on inflammatory diseases. LM metabololipidomics approach allows the assessment of the efficacy of novel treatments with SPMs and low-dose CO. Moreover, this approach indicates the regions where the action of individual LMs may be physiologically relevant and when these LMs are produced in vivo to serve their proresolving mediator functions that may also permit new directions for treating human diseases.
急性炎症是一种基本的保护性反应,它协调免疫系统应对来自体内和外部入侵的有害刺激。新证据表明,急性炎症的消退并非简单的被动过程,而是由新的强效生物活性脂质介质(LMs)家族协调的主动且高度调节的过程,这些介质被称为特殊促消退介质(SPMs)。这些SPMs由n-3多不饱和脂肪酸生物合成。低浓度的SPM(纳摩尔范围)刺激促消退细胞过程,如抑制中性粒细胞浸润、增强巨噬细胞对细菌的吞噬作用和对细胞碎片的胞葬作用,以及通过特定的G蛋白偶联受体减轻炎性疼痛。在调节炎症消退的众多生物活性介质中,低剂量一氧化碳(CO)作为一种组织保护气体递质,由血红素加氧酶(HO)系统内源性产生。特定的SPMs激活HO系统,进而局部增强内源性CO的产生,从而在SPMs和CO之间建立起保护性的正反馈回路。此外,低剂量CO和SPMs治疗通过减少白细胞与血小板的相互作用以及促炎LMs水平,对缺血/再灌注损伤发挥保护作用。本文综述的近期研究评估了SPMs和低剂量吸入CO对炎症性疾病的影响。LM代谢脂质组学方法能够评估SPMs和低剂量CO新疗法的疗效。此外,这种方法还能指出各个LMs的作用在生理上可能相关的区域,以及这些LMs在体内产生以发挥其促消退介质功能的时间,这也可能为治疗人类疾病指明新方向。